News | Sutro Biopharma, Inc.

41st Annual JP Morgan Healthcare Conference – Presentation

41st Annual JP Morgan Healthcare Conference – Presentation Webcast...

Update on STRO-002 Program and Plans for Registrational Trial in Advanced Ovarian Cancer – Presentation

Update on STRO-002 Program and Plans for Registrational Trial in Advanced Ovarian Cancer – Presentation Webcast...

Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer

Events, News, Presentations, Press Releases

Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer – Results from the STRO-002 (luvelta) Phase 1 dose-expansion study demonstrate that FolRα-selected...

Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

Events, News, Presentations, Press Releases

Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., January 4, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer

Events, News, Presentations, Press Releases

Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer – Conference call and webcast to be held on Monday, January 9, 2023 at 1:30 pm PT, or 4:30 pm ET – SOUTH SAN FRANCISCO, Calif., December...

Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract

News, Press Releases

Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract – New Agreement Provides Vaxcyte Access to Expanded Rights to Develop and Manufacture Cell-Free Extract, a Key Component of...